Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury - 09/12/18
páginas | 7 |
Iconografías | 9 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | Teneligliptin suppresses H/R-induced oxidative stress and cell death. |
• | Teneligliptin ameliorates H/R-induced reduction of MMP. |
• | Teneligliptin reduces H/R-caused IL-1β and TNF-α production. |
• | Teneligliptin inhibits attachment of monocytes to endothelial cell via ICAM-1. |
• | Teneligliptin suppresses the expression of Egr-1. |
Abstract |
Cardiovascular complications are the main causes of mortality in diabetic patients. Teneligliptin is a newly developed anti-diabetic agent. It has been reported that teneligliptin has a vascular protective capacity in preclinical studies and diabetes patients. In this study, we investigated the effect of teneligliptin on hypoxia/reoxygenation (H/R)-induced endothelial cell injury in rat cardiac microvascular endothelial cells (CMECs). We showed that teneligliptin pretreatment suppressed H/R-induced production of reactive oxygen species (ROS), NADPH oxidase 4 (NOX4) expression and promoted glutathione production. Teneligliptin pretreatment reduced H/R-induced LDH release and improved cell viability. Teneligliptin significantly relieved the reduction in mitochondrial membrane potential (MMP) induced by H/R. Moreover, teneligliptin suppressed H/R-induced cytokine production and production of vascular adhesion molecules such as IL-1β, TNF-α and ICAM-1. Mechanistically, we showed that teneligliptin inhibited the expression of transcriptional factor Egr-1, which regulates cytokine production and vascular adhesion. Collectively, our data support the notion that teneligliptin is a protective agent in CMECs and has the potential for therapeutic use in the treatments of vascular complications in diabetes patients.
El texto completo de este artículo está disponible en PDF.Keywords : Teneligliptin, Cardiac microvascular endothelial cells (CMEC), Hypoxia/reoxygenation (H/R), Egr-1, Vascular protection
Esquema
Vol 109
P. 468-474 - janvier 2019 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?